Muscle Weakness

Subscribe to Selected New Research on Muscle Weakness

1659 relevant articles (88 outcomes, 85 trials/studies) found for this Disease

Description: A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)

Also Known As:

Muscular Weakness; Muscle Weaknesses; Muscular Weaknesses; Weakness, Muscle; Weakness, Muscular; Weaknesses, Muscle; Weaknesses, Muscular

Relationship Network

Disease Context: Research Results

Musculoskeletal Diseases: 87

Muscular Diseases: 4376

Muscle Weakness: 1659

Nervous System Diseases: 3643

Neurologic Manifestations: 3015

Neuromuscular Manifestations: 11

Muscle Weakness: 1659

Signs and Symptoms Pathological Conditions

Pathologic Processes: 2442

Muscle Weakness: 1659

Signs and Symptoms

Neurologic Manifestations: 3015

Neuromuscular Manifestations: 11

Muscle Weakness: 1659

Related Diseases

1.	Pain (Aches)
2.	Ophthalmoplegia (External Ophthalmoplegia)
3.	Atrophy
4.	Fatigue
5.	Dermatomyositis (Dermatopolymyositis)

Experts

1.	Herzog, Walter: 3 articles (11/2005 - 03/2005)
2.	Longino, David: 2 articles (11/2005 - 03/2005)
3.	Frank, Cy: 2 articles (11/2005 - 11/2005)
4.	Drummond, A D: 1 article (05/2008)
5.	Williamson, R M: 1 article (05/2008)
6.	Rothwell, M P: 1 article (05/2008)
7.	Silverdale, M A: 1 article (05/2008)
8.	Maddali, Madan Mohan: 1 article (10/2007)
9.	Justiniano, Maria: 1 article (10/2007)
10.	Mathew, Jotish: 1 article (10/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Muscle Weakness:

1.	Prednisolone (Predate)FDA LinkGeneric 07/01/2002 - "The patient was treated with prednisolone, 60 mg/day, which completely cured his muscle weakness and difficulty in walking, and sensory disturbance was gradually alleviated. " 11/01/2001 - "Oral prednisolone (1-2 mg/kg/day) was given in 6 cases and the muscle weakness improved. " 05/01/2000 - "With oral prednisolone administration, muscle weakness and other clinical features improved gradually. " 08/01/1992 - "Treatment with prednisolone improved muscular weakness and the slow NCV. " 01/01/1989 - "Treatment with prednisolone improved muscle weakness, urinary difficulties and struma. " Order ALL the reference details at left...
2.	AntibodiesIBA 01/01/1987 - "However, some patients with severe muscle weakness had low titers of antibodies, and some patients in remission or with only ocular manifestations had high titers. " 12/16/2000 - "The diagnosis is clinical, based mainly on the characteristics of the muscle weakness and motor disorders, confirmed by serological methods (demonstration of antibodies) pharmacological and electromyographic tests, by imaging studies and in some cases biopsy. " 08/01/2003 - "CONCLUSION: Patients with GBS and anti-GM1 antibodies had more distal muscle weakness, fewer sensory deficits, more axonal degeneration and C. " 10/01/2001 - "Titers of the antibodies decreased after recovering from muscle weakness of upper limbs. " 03/01/2001 - "These antibodies cause loss of AChR numbers and function, and lead to failure of neuromuscular transmission with muscle weakness. " Order ALL the reference details at left...
3.	EnzymesIBA 12/01/1989 - "Despite the fact she became euthyroid with the treatment, muscle weakness as well as elevated concentrations of muscle enzymes were not improved. " 04/01/2003 - "Despite our reduced number of study samples, our study also suggests a relationship between severe muscle weakness and high seric muscle enzymes." 08/01/2001 - "The amyopathic state is defined by a lack of muscle weakness and through diagnostic tests, including serum muscle enzymes, electromyogram studies, and muscle biopsies, that are usually normal or show only minimal abnormalities. " 06/01/2009 - "IIMs are characterized by the presence of proximal muscle weakness, increased levels of muscle-specific enzymes, specific electromyographic abnormalities, and the presence of inflammatory cell infiltrates in skeletal muscle. " 04/01/2009 - "After one month, he developed muscle weakness, Gottron's papules and elevated serum muscle enzymes. " Order ALL the reference details at left...
4.	Intravenous Immunoglobulins (IVIG)FDA Link 01/01/2007 - "After IVIG, the muscle weakness of the distal upper extremities improved together with increased F wave-evoked frequencies. " 06/01/2003 - "Since the first IVIg mildly improved muscle weakness, we tried the second IVIg of PEG-glob. " 03/01/2003 - "CONCLUSIONS: Despite the introduction of IVIG, 23% of children with GBS had evidence of long-term mild muscle weakness, with minimal impact on function. " 11/01/1997 - "However, after six months of maintenance IVIg treatment (0.4 g/kg weekly) muscle weakness gradually deteriorated below pretreatment levels despite continued treatment. " 08/01/2007 - "Intravenous immunoglobulin therapy (IVIg 0.4 g/kg x 5 days) markedly reduced the severe pain and muscle weakness in the legs. " Order ALL the reference details at left...
5.	Immunoglobulins (Immunoglobulin)IBA 05/01/1999 - "After an administration of 25 g/day of human gamma-immunoglobulin for 5 days, conduction block as well as F-wave abnormalities in the left median and left ulnar nerve were improved, yet no improvement of muscle weakness was seen. " 07/01/2002 - "A treatment by corticoid and secondary intravenous immune globulins because of corticoid-resistance of the dermatopolymyositis and oesophagus injury led to a significant improvement of the cutaneous signs and of the muscular weakness. " 01/01/2007 - "The intravenously administered immunoglobulin (IVIG) treatment that she received several times over a 3-year period relieved her clinical symptoms of muscle weakness and sensory disturbances, but these symptoms had worsened thereafter despite further IVIG treatment. " 10/24/2000 - "BACKGROUND: Immunoglobulin (Ig) administration induces remyelination in the Theiler's virus model of MS. METHODS: A randomized, double-blinded, placebo-controlled trial of IV immunoglobulin (IVIg) was performed in patients with MS who had persistent muscle weakness that had been stable for between 4 and 18 months to determine whether this would improve muscle strength (primary outcome: isometric muscle strength). " 02/01/2008 - "Autosomal recessive spinal muscular atrophy with respiratory distress type 1 (SMARD1), recently referred to as distal spinal muscular atrophy 1 (DSMA1; MIM#604320) and also known as distal hereditary motor neuropathy type 6 (dHMN6 or HMN6), results from mutations in the IGHMBP2 gene on chromosome 11q13.3 encoding the immunoglobulin micro-binding protein 2. In contrast to the infantile spinal muscular atrophy type 1 (SMA1; Werdnig-Hoffmann disease) with weakness predominantly of proximal muscles and bell-shaped thorax deformities due to intercostal muscle atrophy, infants with distal spinal muscular atrophy 1 usually present with distal muscle weakness, foot deformities, and sudden respiratory failure due to diaphragmatic paralysis that often requires urgent intubation. " Order ALL the reference details at left...
6.	Methylprednisolone FDA LinkGeneric 10/01/1998 - "After methylprednisolone pulse therapy, muscle weakness and sensory disturbance improved. " 01/01/2009 - "He was treated with high dose methylprednisolone, which caused severe aggravation of muscle weakness. " 01/01/2008 - "The muscle weakness and respiratory failure gradually improved after intravenous methylprednisolone administration, and the serum CK level was normalized in several days. " 09/01/1999 - "Pulse methylprednisolone therapy for arthritis causing muscle weakness." 01/01/1983 - "A high dose of methylprednisolone (pulse therapy) was given to 3 patients with uncontrolled dermatomyositis (DM) accompanied by severe muscle weakness. " Order ALL the reference details at left...
7.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/01/1997 - "Muscle weakness gradually improved after cyclophosphamide therapy. " 10/01/2007 - "Cyclophosphamide pulse therapy was started and resulted in a marked recovery from muscle weakness, paresthesia and urinary retention, and she could discharge. " 10/01/2007 - "We conclude that steroid and cyclophosphamide pulse therapy for a SLE patient with CNS lupus and lupus myelitisis is effective for ameriolation of symptoms such as disorientation, convulsion, urinary retension, fecal incontinence, muscle weakness and paresthesia in the lower limbs as well as elevated level of serum anti-ribosomal P antibody." 10/01/2004 - "Although the symptoms of CNS lupus did not respond to prednisolone, twelve monthly cyclophosphamide pulse therapy (IV-CY) has resolved urinary disturbance, muscle weakness and sensory loss, along with the improvement of both cerebral and spinal MRI images. " 06/01/2003 - "He was successfully treated with methylprednisolone pulse therapy, cyclophosphamide and prostaglandin E 1. The second patient was 77-year old male with pneumoconiosis who experienced muscular weakness of the four limbs in proximity 4 years ago. " Order ALL the reference details at left...
8.	PotassiumIBA 02/01/2007 - "Following fluid expansion and intravenous potassium replacement, the patient progressed to achieve full regression of muscular weakness after one week. " 07/01/2006 - "Immediate potassium supplementation prevents serious cardiopulmonary complications and may hasten the recovery of muscle weakness. " 06/01/2006 - "The affected family members exhibited marked shifts in compound muscle action potential amplitudes on exercise test, and muscle weakness could be induced by potassium loading and cold exposure. " 04/01/2006 - "The patients present with similar clinical features characterized by episodic attacks of muscle weakness and a decrease in blood potassium. " 01/01/2003 - "Patients with muscle weakness had higher mean systolic BP level and lower plasma potassium level than patients without this complaint. " Order ALL the reference details at left...
9.	Acetylcholine (Acetylcholine Chloride)FDA Link 05/15/1999 - "In this study, we show that nasal administration of acetylcholine receptor (AChR) in C57BL/6 mice, before immunizations with AChR in adjuvant, results in delayed onset and reduced muscle weakness compared with control mice. " 01/04/2007 - "It was shown efficient to reduce a form of variable muscle weakness and fatigability typical of the disease and correlated to a block of acetylcholine release. " 01/01/2003 - "Ab against muscle acetylcholine receptor (AChR) cause the muscular weakness that characterizes MG and its animal model, experimental MG (EMG). " 12/01/2002 - "DTB-induced muscle weakness results from a reduction of acetylcholine (ACh) release by mechanisms that are not yet clear. " 01/01/2002 - "The toxins inhibit acetylcholine release from neuromuscular junctions, producing muscle weakness when injected into dystonic muscles. " Order ALL the reference details at left...
10.	OxygenIBA 02/21/2006 - "CONCLUSIONS: In patients with CHF and inspiratory muscle weakness, IMT results in marked improvement in inspiratory muscle strength, as well as improvement in functional capacity, ventilatory response to exercise, recovery oxygen uptake kinetics, and quality of life." 01/01/2001 - "The Russian physician had postulated that lack of oxygen was responsible for muscular weakness at altitude and therefore had planned to study the oxygen content of air and blood on the summit and to administer oxygen to see if it improved performance. " 09/01/2007 - "A need for oxygen is determined by the base pathology a patient suffers which produces immobilization, due to being bedridden and due to the problems which began due to an organic insufficiency associated with muscular weakness, a failure in the respiratory system, insufficient sputum, and cardiovascular alterations. " 01/01/2004 - "This might explain muscle weakness and the reduction of maximal oxygen uptake, as typically seen in CFS patients. " 05/01/1995 - "We have studied eight patients, four with generalized muscle weakness and four with isolated BDP during nocturnal sleep with measurements including oxygen saturation and surface electromyographic (EMG) activity of various respiratory muscle groups. " Order ALL the reference details at left...

Therapies and Procedures

1.	Plasmapheresis 07/01/1999 - "Therapeutic trial of plasmapheresis was effective for her muscle weakness. " 06/15/2003 - "Muscle weakness responded well to double-filtration plasmapheresis (DFPP) followed by i.v.Ig, but relapsed 45 days after the initial treatment. " 01/01/1991 - "Subgrouping of patients according to severity of disease, as measured by disability or muscular weakness, or response to plasmapheresis treatment, also failed to reveal significant associations. " 09/01/2005 - "Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis." 04/15/1990 - "A 7-year-old sexually intact male Labrador Retriever with regurgitation and generalized muscular weakness resulting from acquired myasthenia gravis received 2 plasmapheresis treatments in combination with corticosteroid treatment. " Order ALL the reference details at left...
2.	Drug Therapy (Chemotherapy) 05/01/2003 - "After the second course of chemotherapy, the serum level of antivoltage-gated Ca2+ channel (VGCC) antibody decreased from 190 pg/ml to 120 pg/ml. Marked improvement of the muscle weakness was recognized only after 3 courses of chemotherapy. " 12/01/2008 - "She showed partial response to the treatment, whereas the skin lesions and muscle weakness deteriorated accompanied with bone marrow suppression due to chemotherapy. " 01/01/2007 - "Chemotherapy and physiotherapy alleviated neurological muscle weakness but did not have any effect on the hip functionality. " 12/01/1998 - "Other factors that may influence the craniofacial growth are head posture, soft tissue stretching, disease activity and drug therapy, type of onset of the disease, muscle weakness, decreased functional ability, and orthodontic treatment." 09/27/1984 - "2: Drug therapy of stress incontinence, bladder muscle weakness and increased bladder outflow resistance]" Order ALL the reference details at left...
3.	Parathyroidectomy 01/01/1987 - "After subtotal parathyroidectomy, we observed a marked improvement in respiratory muscle strength (27 vs. 87 cm H2O) and disappearance of proximal muscle weakness." 09/01/2004 - "OBJECTIVE: To evaluate the effects of parathyroidectomy on the nonspecific symptoms associated with primary hyperparathyroidism, with an emphasis on distinguishing sleepiness from muscle weakness. " 06/01/1981 - "Symptoms relieved by parathyroidectomy included bone pain, pruritus, soft tissue calcification, muscle weakness and healing of fractures. " 10/01/1991 - "Our study documents the following: (1) only 2 of 103 (2%) patients referred for parathyroidectomy had "true" asymptomatic hyperparathyroidism; (2) only symptoms of fatigue, bone pain, and weight loss correlated with the degree of hypercalcemia, whereas muscular weakness, psychiatric symptoms, nocturia, polyuria, recent memory loss, constipation, and nephrolithiasis did not; (3) only 1 of 15 patients who were referred as asymptomatic were truly asymptomatic after more thorough questioning, and all 14 improved following parathyroidectomy; (4) 81% of the patients who were referred with symptoms improved following parathyroidectomy; and (5) permanent complications occurred in only 4 patients. " Order ALL the reference details at left...
4.	Aftercare (After-Treatment) 03/01/1976 - "In two of the cases a return to the euthyroid state after treatment was associated with marked clinical improvement in muscle weakness. " 12/01/1994 - "End points assessed before and after treatment schedules were neurological disability score; muscle weakness of the neurological disability score; summated compound muscle action potentials of ulnar, median, and peroneal nerves; summated sensory nerve action potentials of ulnar and sural nerves; and vibratory detection threshold of the great toe using CASE IV. Observers were masked as to treatment used. " 07/01/1993 - "Clinical observation of several hundred Ilizarov patients has demonstrated prolonged muscle weakness in the involved limb after treatment. " 01/01/1984 - "Through early synovectomy, before cartilage damage and osteoarthritis appear, the infected focus can be "excised." Functional after-treatment avoids cartilage atrophy, wound adhesions, and muscle weakness. " 08/01/2006 - "After treatment with mexiletine, cooling and exercise induced almost no muscle weakness and no changes in 23Na MR signal intensity in patients. " Order ALL the reference details at left...
5.	Thymectomy 04/01/2000 - "After thymectomy, the muscle weakness markedly improved as well as waning in the thenar muscles (11%). " 07/01/1990 - "His muscular weakness and sensory disturbance improved gradually after thymectomy. " 07/01/1999 - "An encapsulated thymoma in the anterior mediastinum was resected as extended thymectomy by video-assisted thoracoscopic surgery at 2 months after the onset of ptosis and muscle weakness. " 05/01/1981 - "[Clinical results of thymectomy in myopathy patients depending on the degree of muscular weakness]" 03/01/2006 - "In the absence of relevant criteria arguing for Myasthenia Gravis (significant variability of muscle weakness, positive titer of anti-AChR or anti-MuSK antibodies, decremental EMG response), a muscle biopsy is required before indication of thymectomy to exclude a mitochondrial disease." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Muscle Weakness

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 88 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>